

Innovative Strategies for Reducing the Environmental Impact of Pharmaceutical Substances

Roadshow «RI-CERR-care il futuro: Innovazione, Ricerca e Trasferimento Tecnologico in Emilia Romagna», Tappa #4, 24 giugno 2026

Ruggero Bettini, Dipartimento di Scienze degli Alimenti e del Farmaco
ruggero.bettini@unipr.it


Pharmaceuticals: Healing and Polluting

The widespread use of drugs represents an indisputable benefit for society but is accompanied by significant ecotoxicological risks.



"Sustainable development is development that meets the needs of the present without compromising the ability of future generations to meet their own needs."

World Commission on Environment and Development,
Our Common Future, Oxford University, 1987




**Environmental
dispersion**
BIOMAGNIFICATION

The most common drugs in the world's rivers

The highest concentrations of APIs were detected in sub-Saharan Africa, South Asia and South America.



DETECTION FREQUENCY



THE STUDY IN NUMBERS

1.052 sampling sites

140 countries across 6 continents

61 active pharmaceutical ingredients monitored

Hormones, steroids, antibiotics, NSAIDs, antiepileptic drugs, antidepressants — stable molecules, poorly metabolized, with low removal rates in wastewater treatment plants.

Poorly soluble drugs persist in the environment

Lipophilic drugs are less likely to remain dissolved in water and have affinity for sediments and biological tissues, increasing their persistence in the environment and contributing to biomagnification

Class I high solubility high permeability	Class II LOW solubility high permeability <i>Carbamazepine, Ibuprofen, Naproxen,</i>
Class III high solubility low permeability	Class IV LOW solubility low permeability <i>Furosemide, Hydrochlorothiazide</i>

CARBAMAZEPINE: the most frequently detected drug
Carbamazepine persists in wastewater, where it can show a dissipation half-life of 74–82 days.



Drug life cycle: hotspots and drug-delivery strategies

The most critical hotspot is excretion: formulation can act on excretion to reduce impact before it becomes an emission


DRUG-DELIVERY STRATEGIES

1. Increase bioavailability

lower dose, lower active excretion

2. Degrade the unabsorbed fraction

In situ before excretion in the drug life cycle



Environmental risk assessment: PEC/PNEC

The risk quotient (RQ) measures the toxicity of a drug for aquatic ecosystems

THE RISK QUOTIENT (RQ)

$$\mathbf{RQ} = \frac{\mathbf{MEC}}{\mathbf{PNEC}}$$

MEC — maximum measured environmental concentration

PNEC — predicted no-effect concentration, the lowest value among LC₅₀, EC₅₀ or NOEC.

PEC — predicted environmental concentration of a substance

RISK CLASSES

Low	RQ < 0.1
Medium	RQ < 1
High	RQ ≥ 1

DECISION THRESHOLD for marketing authorization — PEC/PNEC

PEC/PNEC < 1 → environmental risk unlikely

PEC/PNEC ≥ 1 → the substance is considered toxic

the applicant must provide additional data and risk management and mitigation measures before authorization.



Review

Drugs as contaminants of emerging concern: preventive approaches beyond detection, regulatory aspects and remediation


Umberto Cancelli, Eride Quarta, Davide D'Angelo, Gianluca Bazzoli, Annalisa Bianchera, Ruggero Bettini*

Department of Food and Drug Sciences, University of Parma, Parco Area delle Scienze 27/A, 43124 Parma, Italy




Biodegradable excipients to improve the bioavailability of poorly soluble drugs

Preparation of an amorphous spray-dried powder of the CBZ and M-β-CD complex in a 1:2 molar ratio




Cs raw material 0.149 mg/ml
Cs complex 3.0 mg/ml



Complexation of CBZ with M-β-CD increases solubility 20-fold and permeability across Caco-2 cells 8-fold compared with the raw material

Development of a sequential controlled-release oral system

Gastro-resistant tablets with sequential release of the drug and enzyme in the gastrointestinal tract to reduce environmental impact



Gastric tract
API is released and absorbed

API
Carbamazepine (CBZ)

Intestinal tract
ENZYMES are released in the distal colon
and inactivate unabsorbed active API

ENZYME + MEDIATOR
Laccase and vanillin

Environmental impact
Less API is excreted into the environment

GASTRO-RESISTANT SYSTEM
Eudragit S100 blended with lipids

Enzymatic degradation of CBZ before excretion


Batch #	Eudragit S100 % (w/w)	Lipid A % (w/w)	Lipid B % (w/w)
Lipid A 20	80	20	-
Lipid A 35	65	35	-
Lipid A 50	50	50	-
Lipid B 20	80	-	20
Lipid B 35	65	-	35
Lipid A 50	50	-	50

Batch#	P _y (MPa)	2P _y (MPa)	3P _y (MPa)
Lipid A 20	175.93 ± 4.12	351.86	527.79
Lipid A 35	156.20 ± 0.46	312.40	468.60
Lipid A 50	135.73 ± 0.90	271.46	407.19
Lipid B 20	224.80 ± 25.20	449.60	674.40
Lipid B 35	149.00 ± 8.83	298.00	447.00
Lipid B 50	110.90 ± 4.11	221.8	332.70

Powder mixture and relevant tablet composition (% w/w).



Enzymatic degradation of CBZ before excretion

Optimization of the drug delivery system



Enzymatic degradation of CBZ before excretion

The gastro-resistant laccase–vanillin enzyme tablet degrades 15% of CBZ in 24 hours in gastrointestinal fluid



Laccase/ mediator vanillin ratio to degrade CBZ at a concentration of 15µg/mL.

Environmental risk estimate: Risk Quotient (RQ)

Estimated effect of the improvement on the share of CBZ excreted into the environment — Risk Quotient (MEC/PNEC)

TEGRETOL®
Carbamazepine raw material

400 mg administered dose


30% (≈ 120 mg) amount excreted into the environment

Environmental concentration MEC = 0.345–1 $\mu\text{g/L}$

RISK QUOTIENT (RQ)
14 - 40

HIGH RISK

≈ 20 -fold
reduction in
environmental
risk



SPRAY-DRIED POWDER
CBZ/M- β -CD complex

20 mg estimated dose

About 3 mg reaches the environment

Environmental concentration MEC = 0.02–0.05 $\mu\text{g/L}$

RISK QUOTIENT (RQ)
0.6 - 1.7

REDUCED RISK

*Theoretical estimate based on in vitro tests. A real dose would require bioavailability, pharmacokinetic, metabolism and clinical efficacy data.

24 / 06 / 2026 – Tecnopolo di Parma

μCT analysis of tablet structural changes upon aqueous coating


Aqueous coatings represent a more sustainable alternative to organic solvent-based coatings

Unveiling tablet structural changes: A micro computed tomography analysis of aqueous coating effects



Davide D'Angelo, Eride Quarta, Gianluca Bazzoli, Annalisa Bianchera, Ruggero Bettini*

Department of Food and Drug Sciences, University of Parma, Parco Area delle Scienze 27/A, Parma 43124, Italy

Porosity study (XμCT)



Pan Coating Process



	MCC	CPFX	SSG	MS
Batch 1	74	25	0	1
Batch 2	49	50	0	1
Batch 3	24	75	0	1
Batch 4	72	25	2	1
Batch 5	47	50	2	1
Batch 6	22	75	2	1
Batch 7	69	25	5	1
Batch 8	44	50	5	1
Batch 9	19	75	5	1



Powder mixture and relevant tablet composition (% w/w). MCC =Microcrystalline cellulose; CPFX =Ciprofloxacin; SSG =Sodium starch glycolate; MS=Magnesium stearate.


Coating

-HPMC + PEG


-Eudragit® FS30D (water based dispersion)

Aqueous coating induces structural changes and increased porosity in tablets







Experimental and calculated (C) brittle (Db) and plastic (Dp) relative density values from Heckel plot analysis of the mixtures. The bars represent the standard deviation (n=3).



Percentage of in-die and out-die elastic recovery (Er) of single components of the mixtures and blends. MCC: microcrystalline cellulose; MS: magnesium stearate; CPMX: ciprofloxacin with 1 % (w/w) of MS. Data are expressed as mean and standard deviation from n=3 experiments.



Porosity percentage of uncoated tablets (black bars), after HPMC coating (grey bars) and after further coating with 5 % (dotted bars) and 10 % (w/w) (bars with lines) with Eudragit® FS30D. The bars represent the standard deviation (n=3).



Disintegration time of tablets, before coating (Uncoated, black bars) and after HPMC coating (grey bars) in distilled water and after 10 % (w/w) Eudragit® FS30D coating at pH 1.2 (blue bars). Data are expressed as mean and standard deviation from n=6 experiments.



Finanziato dall'Unione europea
NextGenerationEU



Ministero dell'Università e della Ricerca



Italiadomani
PIANO NAZIONALE DI RIPRESA E RESILIENZA

in collaborazione con



ART-ER
ATTRATTIVITÀ
RICERCA
TERRITORIO



ALMA MATER STUDIORUM
UNIVERSITÀ DI BOLOGNA
DIPARTIMENTO DI FISICA E ASTRONOMIA
"AUGUSTO RIGHI"



Università degli Studi di Ferrara



UNIMORE
UNIVERSITÀ DEGLI STUDI DI
MODENA E REGGIO EMILIA



UNIVERSITÀ DI PARMA



Consiglio Nazionale delle Ricerche



ENEA
Agenzia nazionale per le nuove tecnologie, l'energia e lo sviluppo economico sostenibile



UNIVERSITÀ CATTOLICA del Sacro Cuore



POLITECNICO MILANO 1863



INFN
Istituto Nazionale di Fisica Nucleare



ALMACUBE
Advanced Manufacturing Center of Excellence



bi-REX
Big Data Innovation & Research Excellence



CENTRO CERAMICO



certimac | INd.COR



CINECA



CRPA



DEMOCENTER



FONDAZIONE REI



LEAP
Laboratory of Energy and Advanced Production



MISTER
SMART INNOVATION



MUSP
Macchine Utensili e Sistemi di Produzione



PROAMBIENTE
Innovation & environment



romagnatech
INNOVATION VALUE



t3lab
TECHNOLOGY TRANSFER TEAM



TDM
TECNOLOGIA DI MODENA



TECNOPOLO REGGIO-EMILIA
EMILIA-ROMAGNA